石四藥集團有限公司
SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT
UPDATE ON PRODUCT DEVELOPMENT

The board of directors (the "Board") of SSY Group Limited (the "Company", together with its subsidiaries, the "Group") is pleased to announce that the Group has obtained the approval for drug production and registration for 0.4ml Ketotifen Fumarate Eye Drops in unit dose packaging (0.025%) (the "Product") from National Medical Products Administration of China (the "NMPA"), being under type 3 chemical drug and regarded as passing the consistency evaluation. The Product is mainly used in symptomatic treatment of seasonal allergic conjunctivitis. The Product is the second of such approvals for the PRC entities, and is the Group's third type of ophthalmic preparation medicines.

The Board is also pleased to announce that the Group has obtained the approval for drug production and registration for Calcium Gluconate Injection (10ml:1g) from the NMPA, being under type 3 chemical drug and regarded as passing the consistency evaluation. Calcium Gluconate Injection is mainly used for the treatment of acute hypocalcemia, magnesium poisoning and fluoride poisoning.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board
Chow Hing Yeung
Executive Director and Company Secretary

Hong Kong, 18 July 2025

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo, Mr. Chow Hing Yeung and Ms. Qu Wanrong as executive Directors, Mr. Liu Wenjun as non-executive Director, and Mr. Wang Yibing, Mr. Chow Kwok Wai and Mr. Jiang Guangce as independent non-executive Directors.